Zika vaccines and immunogenic compositions, and methods of using the same

A method of treating or preventing Zika virus infection in a human subject population in need thereof, comprising administering to individual human subjects of said human subject population a vaccine or immunogenic composition comprising antigen from a Zika virus, wherein the vaccine or immunogenic composition is administered as a single dose or prime administration, and wherein the administration of the vaccine or immunogenic composition induces 14 and/or 28 days after the single dose or prime administration geometric mean neutralizing antibody titers in a population of at least 20 flavivirus naïve human subjects and/or in a population of at least 20 Zika virus seronegative human subjects of greater than 10, as determined by the plaque reduction neutralization test (PRNT).

A Method of treating or preventing Zika virus infection in a human subject population in need thereof, comprising administering to individual human subjects of said human subject population a vaccine or immunogenic composition comprising antigen from a Zika virus, wherein the vaccine or immunogenic composition is administered as single dose or prime administration and wherein the administration of the vaccine or immunogenic composition induces 14 and/or 28 days after the single dose or prime administration a seroconversion rate of at least 25%, in a population of at least 20 Zika virus seronegative human subjects, as determined by the plaque reduction neutralization test (PRNT).